SCHEMBL5840567

SCHEMBL5840567

COC(=O)c1cc(Sc2cccc(Oc3ccccc3)c2)c([N+](=O)[O-])s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XDH P47989 2/20 0.41
TLR4 O00206 1/20 0.40
TLR2 O60603 1/20 0.40
EDNRA P25101 1/20 0.39
USP47 Q96K76 1/20 0.38
MAPT P10636 3/20 0.38
FFAR1 O14842 2/20 0.38
GAA P10253 1/20 0.38
KDM4E B2RXH2 1/20 0.38
USP10 Q14694 1/20 0.38
HTT P42858 2/20 0.38
ICAM1 P05362 1/20 0.37
SELE P16581 1/20 0.37
VCAM1 P19320 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
FBP1 P09467 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5840563 0.90 EDNRA (0.43) EDNRAMAPTGAAKDM4EHTT
SCHEMBL5839296 0.85 ALDH1A1 (0.43) USP47MAPTGAAKDM4EUSP10
SCHEMBL5841470 0.84 ICAM1 (0.39) USP47MAPTGAAUSP10HTT
SCHEMBL5841158 0.79 ICAM1 (0.40) USP47MAPTGAAKDM4EHTT
SCHEMBL5840146 0.77 XDH (0.43) XDHFFAR1GAAKDM4EUSP10
SCHEMBL5840639 0.77 MAPT (0.41) MAPTKDM4EHTTALDH1A1HPGD
SCHEMBL6491122 0.75 C1S (0.41) MAPTGAAKDM4EICAM1SELE
SCHEMBL21436430 0.72 USP10 (0.65) XDHUSP47MAPTKDM4EUSP10
SCHEMBL5841225 0.72 ICAM1 (0.43) USP47MAPTGAAKDM4EHTT
SCHEMBL5841241 0.71 ICAM1 (0.41) MAPTGAAKDM4EUSP10HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7138530-B2 Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2006-11-21 US disclosed
US-7109354-B2 Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2006-09-19 US disclosed
EP-1549632-A4 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS DIMENSIONAL PHARM INC (US) 2005-11-09 EP disclosed
US-20050234081-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions SUBASINGHE NALIN 2005-10-20 US disclosed
EP-1549632-A1 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2005-07-06 EP disclosed
US-20040009995-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. 2004-01-15 US disclosed
WO-2003099805-A1 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234081-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions C5, C9, C1R XDH 327/4885TLR4 30/4885TLR2 114/4885
US-20040009995-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions C5, C9, C1R XDH 437/4885TLR4 30/4885TLR2 92/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.